BACE1 and Alzheimer disease: In addition, some multitarget therapeutic strategies for AD proposed dual compounds that would allow the inhibition of ChE and BACE1 or that can inhibit ChE and Glycogen synthase kinase-3β (GSK-3β) or ChE and monoamine oxidase (MAO) enzyme, and other combinations of compounds that may influence ChE and receptors.